The Mayo Clinic explains that medicines affecting blood sugar may lead to temporary adjustment issues
SCN9A variants may be implicated in neuropathic pain associated with diabetic peripheral neuropathy and pain severity
Over time, my symptoms escalated to migraines, vertigo, heart palpitations, anxiety, panic attacks, acid reflux, seborrheic dermatitis, and low blood pressure
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days [1] , approved for chronic weight management and glycemic control
These studies will provide more definitive answers about efficacy, optimal dosing, patient selection criteria, and safety considerations
Studies show users consume materially fewer calories than before